The Fiscal Policy Podcast with Fexingo: Government Budgets, Stimulus, and Public Spending

Fexingo

Lucas and Luna dissect the machinery of public finance — how governments borrow, spend, and tax — without the political theater. Each episode examines a single fiscal lever: a stimulus check's ripple through consumer debt, the bond market's reaction to a budget deficit, or the real cost of infrastructure spending. Lucas traces the Treasury's cash flows with a fountain pen across an abstract budget breakdown, while Luna presses on the human outcomes: which households actually benefit from a child tax credit, why a state's pension gap widens, or how procurement rules inflate the price of a new highway. The show serves economists, policy analysts, and investors who need to understand fiscal reality as it unfolds — not as campaign slogans. Expect granular case studies, from Japan's lost-decade stimulus to the U.S. inflation reduction act's supply-chain effects, with both hosts citing specific CBO scores, IMF working papers, and Federal Reserve research. They never forecast without data, never moralize, and never reduce a trillion-dollar decision to a soundbite. By the end, you'll know why the yield curve inverted — and why it matters for the next round of municipal bonds you're holding. #FiscalPolicy #GovernmentBudget #PublicSpending #Stimulus #NationalDebt #TaxPolicy #MonetaryPolicy #FederalReserve #TreasuryBonds #Infrastructure #DeficitSpending #Economics #FexingoBusiness #BusinessPodcast #Business #Macroeconomics #FiscalMultiplier #CBO Keep every episode free: buymeacoffee.com/fexingo

  1. 3d ago

    How Government Subsidies Create Billion-Dollar Drug Shortages

    This episode of The Fiscal Policy Podcast with Fexingo examines how the U.S. government's own subsidy programs inadvertently cause chronic shortages of critical generic drugs. Lucas and Luna dive into the 2024-2025 shortage of generic chemotherapy drugs, tracing the root cause to a combination of Medicare reimbursement caps and FDA orphan drug incentives that push manufacturers away from low-margin generics toward high-margin specialty drugs. They zero in on the case of cisplatin and carboplatin — two cheap, essential cancer drugs that suddenly became scarce in 2024 despite decades of stable supply. The hosts explain how a 2022 law intended to boost domestic manufacturing actually made things worse by subsidizing factory construction without guaranteeing purchase commitments. By July 2026, the Government Accountability Office estimates that 70 percent of generic drug shortages involve products where federal subsidies indirectly reduced competition. Specific numbers: 15 generic drug factories closed between 2023 and 2025, and the average price of a course of cisplatin rose from $15 to $350 during the shortage. Lucas and Luna argue that the core problem is misaligned incentives — the government pays for production capacity but doesn't ensure the drugs are actually made. #DrugShortages #GenericDrugs #Medicare #FDA #OrphanDrugIncentives #Cisplatin #Carboplatin #Chemotherapy #GovernmentSubsidies #PharmaceuticalPolicy #GAO #ManufacturingIncentives #FiscalPolicy #Economics #FexingoBusiness #BusinessPodcast #PublicSpending #HealthcarePolicy Keep every episode free: buymeacoffee.com/fexingo

About

Lucas and Luna dissect the machinery of public finance — how governments borrow, spend, and tax — without the political theater. Each episode examines a single fiscal lever: a stimulus check's ripple through consumer debt, the bond market's reaction to a budget deficit, or the real cost of infrastructure spending. Lucas traces the Treasury's cash flows with a fountain pen across an abstract budget breakdown, while Luna presses on the human outcomes: which households actually benefit from a child tax credit, why a state's pension gap widens, or how procurement rules inflate the price of a new highway. The show serves economists, policy analysts, and investors who need to understand fiscal reality as it unfolds — not as campaign slogans. Expect granular case studies, from Japan's lost-decade stimulus to the U.S. inflation reduction act's supply-chain effects, with both hosts citing specific CBO scores, IMF working papers, and Federal Reserve research. They never forecast without data, never moralize, and never reduce a trillion-dollar decision to a soundbite. By the end, you'll know why the yield curve inverted — and why it matters for the next round of municipal bonds you're holding. #FiscalPolicy #GovernmentBudget #PublicSpending #Stimulus #NationalDebt #TaxPolicy #MonetaryPolicy #FederalReserve #TreasuryBonds #Infrastructure #DeficitSpending #Economics #FexingoBusiness #BusinessPodcast #Business #Macroeconomics #FiscalMultiplier #CBO Keep every episode free: buymeacoffee.com/fexingo